Cargando…

Clinical Features and Cytokine Profile in Myositis Patients with Anti-EJ Autoantibodies Detected by a Novel Immunoprecipitation Assay

OBJECTIVE: This study aimed to clarify the clinical features, the serum level of autoantibodies, and cytokine of myositis patients with anti-EJ antibody, which targets glycyl tRNA-synthetase (GlyRS). METHODS: Sera of 236 Chinese patients with myositis were screened for anti-EJ by a novel immunopreci...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yang, Liu, Yangtengyu, Huang, Li, Wang, Li, Liu, Ke, Liu, Meidong, Luo, Hui, Zuo, Xiaoxia, Li, Yisha, Zhang, Huali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452540/
https://www.ncbi.nlm.nih.gov/pubmed/31019965
http://dx.doi.org/10.1155/2019/1856180
_version_ 1783409310069424128
author Yang, Yang
Liu, Yangtengyu
Huang, Li
Wang, Li
Liu, Ke
Liu, Meidong
Luo, Hui
Zuo, Xiaoxia
Li, Yisha
Zhang, Huali
author_facet Yang, Yang
Liu, Yangtengyu
Huang, Li
Wang, Li
Liu, Ke
Liu, Meidong
Luo, Hui
Zuo, Xiaoxia
Li, Yisha
Zhang, Huali
author_sort Yang, Yang
collection PubMed
description OBJECTIVE: This study aimed to clarify the clinical features, the serum level of autoantibodies, and cytokine of myositis patients with anti-EJ antibody, which targets glycyl tRNA-synthetase (GlyRS). METHODS: Sera of 236 Chinese patients with myositis were screened for anti-EJ by a novel immunoprecipitation assay of flag-tagged GlyRS. Anti-EJ positive patients are evaluated for the clinical features and cytokine profile. RESULTS: The sera from 4 of 236 adult myositis patients were found to carry the anti-EJ using established novel immunoprecipitation assay and immunoblotting. The prevalence of anti-EJ in our cohorts is about 1.7%. The decline of anti-EJ level was detected in two patients during disease remission. Interstitial lung disease and muscle weakness, but not skin involvement, are common clinical features of anti-EJ positive patients. Moreover, using a cytokine profile analyses, we found that the serum levels of IP-10, IL-6, MCP-1, and VEGF were significantly elevated in patients with anti-EJ and gradually decreased during disease remission of two patients, whereas IL-8 level was obviously reduced in these patients. CONCLUSION: The novel immunoprecipitation assay is suitable to detect and monitor the levels of anti-EJ autoantibody. The serum levels of anti-EJ, IP-10, IL-6, MCP-1, and VEGF may be related to disease activity in myositis patients with anti-EJ antibodies.
format Online
Article
Text
id pubmed-6452540
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-64525402019-04-24 Clinical Features and Cytokine Profile in Myositis Patients with Anti-EJ Autoantibodies Detected by a Novel Immunoprecipitation Assay Yang, Yang Liu, Yangtengyu Huang, Li Wang, Li Liu, Ke Liu, Meidong Luo, Hui Zuo, Xiaoxia Li, Yisha Zhang, Huali Biomed Res Int Research Article OBJECTIVE: This study aimed to clarify the clinical features, the serum level of autoantibodies, and cytokine of myositis patients with anti-EJ antibody, which targets glycyl tRNA-synthetase (GlyRS). METHODS: Sera of 236 Chinese patients with myositis were screened for anti-EJ by a novel immunoprecipitation assay of flag-tagged GlyRS. Anti-EJ positive patients are evaluated for the clinical features and cytokine profile. RESULTS: The sera from 4 of 236 adult myositis patients were found to carry the anti-EJ using established novel immunoprecipitation assay and immunoblotting. The prevalence of anti-EJ in our cohorts is about 1.7%. The decline of anti-EJ level was detected in two patients during disease remission. Interstitial lung disease and muscle weakness, but not skin involvement, are common clinical features of anti-EJ positive patients. Moreover, using a cytokine profile analyses, we found that the serum levels of IP-10, IL-6, MCP-1, and VEGF were significantly elevated in patients with anti-EJ and gradually decreased during disease remission of two patients, whereas IL-8 level was obviously reduced in these patients. CONCLUSION: The novel immunoprecipitation assay is suitable to detect and monitor the levels of anti-EJ autoantibody. The serum levels of anti-EJ, IP-10, IL-6, MCP-1, and VEGF may be related to disease activity in myositis patients with anti-EJ antibodies. Hindawi 2019-03-25 /pmc/articles/PMC6452540/ /pubmed/31019965 http://dx.doi.org/10.1155/2019/1856180 Text en Copyright © 2019 Yang Yang et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Yang, Yang
Liu, Yangtengyu
Huang, Li
Wang, Li
Liu, Ke
Liu, Meidong
Luo, Hui
Zuo, Xiaoxia
Li, Yisha
Zhang, Huali
Clinical Features and Cytokine Profile in Myositis Patients with Anti-EJ Autoantibodies Detected by a Novel Immunoprecipitation Assay
title Clinical Features and Cytokine Profile in Myositis Patients with Anti-EJ Autoantibodies Detected by a Novel Immunoprecipitation Assay
title_full Clinical Features and Cytokine Profile in Myositis Patients with Anti-EJ Autoantibodies Detected by a Novel Immunoprecipitation Assay
title_fullStr Clinical Features and Cytokine Profile in Myositis Patients with Anti-EJ Autoantibodies Detected by a Novel Immunoprecipitation Assay
title_full_unstemmed Clinical Features and Cytokine Profile in Myositis Patients with Anti-EJ Autoantibodies Detected by a Novel Immunoprecipitation Assay
title_short Clinical Features and Cytokine Profile in Myositis Patients with Anti-EJ Autoantibodies Detected by a Novel Immunoprecipitation Assay
title_sort clinical features and cytokine profile in myositis patients with anti-ej autoantibodies detected by a novel immunoprecipitation assay
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452540/
https://www.ncbi.nlm.nih.gov/pubmed/31019965
http://dx.doi.org/10.1155/2019/1856180
work_keys_str_mv AT yangyang clinicalfeaturesandcytokineprofileinmyositispatientswithantiejautoantibodiesdetectedbyanovelimmunoprecipitationassay
AT liuyangtengyu clinicalfeaturesandcytokineprofileinmyositispatientswithantiejautoantibodiesdetectedbyanovelimmunoprecipitationassay
AT huangli clinicalfeaturesandcytokineprofileinmyositispatientswithantiejautoantibodiesdetectedbyanovelimmunoprecipitationassay
AT wangli clinicalfeaturesandcytokineprofileinmyositispatientswithantiejautoantibodiesdetectedbyanovelimmunoprecipitationassay
AT liuke clinicalfeaturesandcytokineprofileinmyositispatientswithantiejautoantibodiesdetectedbyanovelimmunoprecipitationassay
AT liumeidong clinicalfeaturesandcytokineprofileinmyositispatientswithantiejautoantibodiesdetectedbyanovelimmunoprecipitationassay
AT luohui clinicalfeaturesandcytokineprofileinmyositispatientswithantiejautoantibodiesdetectedbyanovelimmunoprecipitationassay
AT zuoxiaoxia clinicalfeaturesandcytokineprofileinmyositispatientswithantiejautoantibodiesdetectedbyanovelimmunoprecipitationassay
AT liyisha clinicalfeaturesandcytokineprofileinmyositispatientswithantiejautoantibodiesdetectedbyanovelimmunoprecipitationassay
AT zhanghuali clinicalfeaturesandcytokineprofileinmyositispatientswithantiejautoantibodiesdetectedbyanovelimmunoprecipitationassay